Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
- Trial name
- S1216 (NCT01809691)
- Testing
- TAK-700, Bicalutamide
- Where
- 560 sites in United States
- Volunteers
- 1,313 people
- Sponsor
- SWOG Cancer Research Network
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph…
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01409200
- Testing
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer
Genistein is a natural supplement that comes from soy. The purpose of this study is to see if genistein has any effect on preventing or reducing heart disease and diabetes risk in men receiving Androgen Deprivation Therapy for…
- Trial name
- GeniPro (NCT02766478)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Adenocarcinoma of Prostate, Progression of Prostate Cancer
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with…
- Trial name
- PEACE2 (NCT01952223)
- Testing
- Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy
- Where
- France
- Volunteers
- 761 people
- Sponsor
- UNICANCER
Prostate Cancer
SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
Current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy.
- Trial name
- SATURN (NCT01953055)
- Testing
- Stereotactic ablative radiotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation…
- Trial name
- NCT05879913
- Testing
- Coronary CT Angiography (CCTA)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
Prostate Cancer
Docetaxel in Treating Patients With Relapsed Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482274
- Testing
- docetaxel
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
A Prolonged Nightly Fasting for Men on ADT for PCa
This small study tested a 3-month text-based health coaching program for men with prostate cancer on hormone therapy. The program was feasible and well accepted, with participants showing good engagement and some improvements in…
- Trial name
- NCT07462403
- Testing
- Prolonged Nightly Fasting (PNF+), Healthy Diet Text Messaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thomas Jefferson University
Locally Advanced Malignant Neoplasm
Healthy Bones Study
Prostate cancer patients receiving hormone treatment (androgen deprivation therapy, or ADT) are at increased risk of developing bone loss and osteoporosis as side effects.
- Trial name
- NCT01973673
- Testing
- Bone health educational materials
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Advanced Prostate Carcinoma
Physical Function During ARSI Treatment
This single arm observational pilot study aims to determine the longitudinal effects of androgen receptor signaling inhibitors (ARSI) in men with advanced prostate cancer.
- Trial name
- NCT05612880
- Testing
- androgen receptor signaling inhibitors
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year
The purpose of this study is to evaluate if there is a difference in quality of life (as measured by FACT-P) in patients treated with androgen deprivation therapy (ADT) for biochemical failure (PSA recurrence) following surgery…
- Trial name
- NCT00703768
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Urology South Shore Research Inc.